metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)
versus BSC
	durvalumab plus tremelimumab vs. BSC	1	0.72 [0.54; 0.96], 1 RCT, I2=0% unassessable degree of certainty	1.01 [0.76; 1.34], 1 RCT, I2=0% inconclusive result	-